Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Multi-Indication Pricing: Big Hurdles And Actionable Options

Executive Summary

Pricing drugs differently by indication presents an opportunity to better align the cost of medicines to value in certain cases, but the regulatory, policy and administrative challenges are daunting. Experts debated the challenges and opportunities during the ISPOR annual meeting.

Advertisement

Related Content

Express Scripts Adds Gilead’s Harvoni To 2017 Formularies
Oncology Booming But Cost Outlook Grim, IMS Says
FDA Orphan-Only Review Division Could Speed Access, Gottlieb Suggests
Sanofi/Genzyme Primed Patient Community For Campath’s Removal From Commercial Distribution

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057664

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel